Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

BACKGROUND: The IFCT-GFPC 0502 phase III study reported prolongation of progression-free survival with gemcitabine or erlotinib maintenance vs. observation after cisplatin–gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). This analysis was undertaken to assess the i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Borget, Isabelle, Pérol, Maurice, Pérol, David, Lavolé, Armelle, Greillier, Laurent, Dô, Pascal, Westeel, Virginie, Crequit, Jacky, Léna, Hervé, Monnet, Isabelle, Le Caer, Hervé, Fournel, Pierre, Falchero, Lionel, Poudenx, Michel, Vaylet, Fabien, Chabaud, Sylvie, Vergnenegre, Alain, Zalcman, Gérard, Chouaïd, Christos
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4302067/
https://ncbi.nlm.nih.gov/pubmed/25511923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-953
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados